Ocunova is focused exclusively on developing a new treatment for dry eye syndrome (DES). The lead compound has shown robust activity in diabetics with dry eye in both animal and human studies. Dry Eye in diabetics is a significant problem with an estimated prevalence of 50%. The management team is highly experienced and the company is raising capital for a phase 2b clinical trial.